Arvinas (ARVN) Projected to Post Earnings on Tuesday

Arvinas (NASDAQ:ARVN) will likely be releasing its Q4 2025 results before the market opens on Tuesday, February 10th. Analysts expect the company to announce earnings of ($0.55) per share and revenue of $37.2630 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 12:30 PM ET.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.27. Arvinas had a negative net margin of 18.73% and a negative return on equity of 9.77%. The business had revenue of $41.90 million during the quarter, compared to analyst estimates of $29.36 million. During the same quarter last year, the business earned ($0.68) EPS. The firm’s quarterly revenue was down 59.1% on a year-over-year basis. On average, analysts expect Arvinas to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arvinas Stock Performance

Shares of NASDAQ ARVN opened at $13.83 on Tuesday. The stock has a market cap of $888.16 million, a P/E ratio of -17.07 and a beta of 1.88. The firm has a 50 day moving average price of $12.35 and a two-hundred day moving average price of $9.92. Arvinas has a 52-week low of $5.90 and a 52-week high of $20.38.

Wall Street Analyst Weigh In

Several brokerages have commented on ARVN. Stephens lifted their target price on Arvinas from $14.00 to $15.00 and gave the stock an “overweight” rating in a report on Monday, November 10th. Barclays raised their price target on shares of Arvinas from $16.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. Wells Fargo & Company reduced their price objective on shares of Arvinas from $16.00 to $15.00 and set an “overweight” rating on the stock in a research note on Thursday, November 6th. Piper Sandler reissued an “overweight” rating and set a $16.00 target price on shares of Arvinas in a research note on Tuesday, October 7th. Finally, Citigroup upgraded shares of Arvinas from a “neutral” rating to a “buy” rating and boosted their target price for the company from $10.00 to $15.00 in a report on Tuesday, January 6th. Twelve equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $16.79.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC increased its stake in Arvinas by 491.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock valued at $43,000 after purchasing an additional 4,835 shares in the last quarter. Canada Pension Plan Investment Board grew its stake in shares of Arvinas by 109.4% in the 2nd quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock valued at $49,000 after buying an additional 3,500 shares during the period. Jain Global LLC bought a new stake in Arvinas in the 3rd quarter valued at about $95,000. Oxford Asset Management LLP increased its position in Arvinas by 15.5% in the 2nd quarter. Oxford Asset Management LLP now owns 16,705 shares of the company’s stock valued at $123,000 after buying an additional 2,242 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in Arvinas during the 3rd quarter worth approximately $124,000. 95.19% of the stock is owned by institutional investors.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.